Krystal Biotech, Inc. KRYS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s total equity?
- Krystal Biotech, Inc. (KRYS) reported total equity of $1.28B in Q1 2026.
- How has Krystal Biotech, Inc.'s total equity changed year-over-year?
- Krystal Biotech, Inc.'s total equity increased by 29.7% year-over-year, from $984.67M to $1.28B.
- What is the long-term trend for Krystal Biotech, Inc.'s total equity?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s total equity has grown at a 33.1% compound annual growth rate (CAGR), from $292.08M to $1.22B.
- What does total equity mean?
- The total net value of the company belonging to its shareholders.
- How do you interpret total equity?
- An increase indicates growth in net assets through earnings or capital raises, while a decrease may signal losses or share buybacks.
- How does total equity compare across companies?
- Varies by industry; essential for assessing the solvency of companies with high R&D burn rates.